PharmExec
SEPTEMBER 8, 2023
With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Fierce Pharma
SEPTEMBER 7, 2023
Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 8, 2023
HHS released a new proposed rule to update nearly 50-year old regulations protecting people with disabilities from discrimination while seeking healthcare. With its new proposal, HHS is amending the regulations to be clearer in their language, as well as more aligned with the Americans with Disabilities Act, the Americans with Disabilities Amendments Act and amendments to the Rehabilitation Act.
Clarivate
SEPTEMBER 7, 2023
We are proud to introduce fresh insights into measuring global research performance via our dynamic G20 scorecard for 2023, newly enhanced with online data visualizations. This guide to understanding the G20 scorecard explores how this interactive tool expands our perspective of global research and innovation. Each year, prior to the G20 Summit of the heads of state of the member nations, the Institute for Scientific Information (ISI) at Clarivate releases its annual G20 scorecard.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PM360
SEPTEMBER 7, 2023
The healthcare system might not be too keen to hang this report card on the fridge: 26% of Americans rated their healthcare experience as a D (18%) or an F (8%), while 34% gave it a solid C and only 10% gave it an A, that’s according the American Academy of Physician Associates (AAPA) and The Harris Poll’s survey of 2,519 adults age 18+ conducted between February 23 and March 9, 2023. 1 For 65% of respondents, one of the biggest issues was that coordinating and managing healthcare is overwhelmin
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
SEPTEMBER 7, 2023
The trial analyses the impact of its ‘Neuro-Cells’ among patients with traumatic spinal cord injuries - News - PharmaTimes
Medgadget
SEPTEMBER 7, 2023
Researchers at the University of California San Diego have created a bacterial sentinel system that can alert clinicians to the presence of tumors. The technology takes advantage of the specificity of the CRISPR system and the tendency of bacteria to uptake fragments of DNA from their environment. Termed “Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer” (CATCH), the system has been created to detect gastrointestinal tumors in its first iteration.
Fierce Pharma
SEPTEMBER 6, 2023
IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.
MedCity News
SEPTEMBER 7, 2023
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
European Pharmaceutical Review
SEPTEMBER 8, 2023
Eli Lilly ’s Mounjaro (tirzepatide), has been recommended to treat poorly controlled type 2 diabetes in adults alongside diet and exercise. National Institute for Health and Care Excellence (NICE) final draft guidance recommends tirzepatide as a new treatment option for this indication. Compared with semaglutide , insulin therapy or a placebo, tirzepatide demonstrated that 81 percent to 97 percent of people achieved better glucose control in clinical trials.
Pharmaceutical Technology
SEPTEMBER 5, 2023
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
Fierce Pharma
SEPTEMBER 5, 2023
Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act (IRA). | Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act. The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.
MedCity News
SEPTEMBER 7, 2023
A new survey from Alignment Health found that economic instability, food insecurity, lack of support and transportation access are the biggest social barriers for seniors.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
SEPTEMBER 7, 2023
A Phase I trial employing the drug dasatinib has shown promise in clearing senescent cells in Alzheimer’s. Recent drugs targeting beta-amyloid plaques have only yielded modest results, according to the study researchers. Instead, the current US study pursued cellular senescence as an alternative area of focus. The findings published in Nature Medicine described how the US Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor dasatinib was used in combination with quercetin, a pla
PharmExec
SEPTEMBER 6, 2023
A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.
Fierce Pharma
SEPTEMBER 6, 2023
Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act (IRA). | Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act. But now that the Centers for Medicare & Medicaid Services has released the first 10 drugs set for governmental bargaining, the company is ready to abandon its litigation.
MedCity News
SEPTEMBER 7, 2023
Medicare Advantage beneficiaries with a cancer diagnosis spend $3,996 on out-of-pocket costs and premiums annually, versus $6,091 for traditional Medicare beneficiaries with cancer, a new report found.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
SEPTEMBER 7, 2023
Leveraging PAT for environmental monitoring in light of Annex 1 The pharma industry’s adaptation to Industry 4.0 has been slow, due to the extensive regulatory requirements imposed on manufacturers. However, regulatory agencies are starting to embrace movement towards more rapid/automated systems, as illustrated in the revised EU GMP Annex 1, which is due to enter into force in August.
PharmExec
SEPTEMBER 3, 2023
One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work.
Fierce Pharma
SEPTEMBER 7, 2023
University of Pennsylvania spinout BlueWhale Bio has surfaced on a mission to smash bottlenecks in cell and gene therapy manufacturing. | Cell therapy manufacturer BlueWhale Bio uncloaked Thursday with news it has raised $18 million in seed financing. The funding round was led by Danaher Corporation.
MedCity News
SEPTEMBER 4, 2023
Apprehension among practices and providers is understandable, given the complexity and variance of VBC contracts. However, instead of feeling overwhelmed and burdened by VBC, practices can slowly embrace these concepts by leveraging the many tools they already have in place or that exist in the healthcare ecosystem.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
European Pharmaceutical Review
SEPTEMBER 7, 2023
How breakthrough CAR-T cancer therapies could be made more widely accessible The development and regulatory approval of the first autologous CAR T-cell therapies is a huge advance for modern medicine and has been greeted with justifiable excitement. But applications of this technology are still limited, and given the time and cost constraints, more must be done to broaden access to this treatment.
PharmaVoice
SEPTEMBER 5, 2023
Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.
Fierce Pharma
SEPTEMBER 7, 2023
It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. | Roche may not receive the FDA's decision on a subcutaneous version of its cancer immunotherapy Tecentriq on time thanks to the agency's requirement for changes to the drug's manufacturing process.
MedCity News
SEPTEMBER 5, 2023
CMS released a proposed rule to establish staffing standards among the nation’s nursing homes. Reactions have been mixed — but mainly negative. Long-term care facilities say that they can neither find nor afford more workers. On the other hand, some lawmakers argue the proposed rule doesn’t do enough to protect care quality for patients. As for labor unions, they seem generally happy with the rule.
European Pharmaceutical Review
SEPTEMBER 5, 2023
Novo Nordisk’s semaglutide injection Wegovy ® is now available as a treatment for obesity in the UK. The pharmaceutical company stated it believed that the launch of Wegovy will help provide an additional option to support people living with obesity in the UK. The semaglutide injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management.
PharmExec
SEPTEMBER 8, 2023
Lisa LeCointe-Cephas, SVP, chief ethics and compliance officer and office of general counsel, human health, Merck, uses her unique style of leadership—stop, drop, and roll—while elevating voices that need to be heard.
Fierce Pharma
SEPTEMBER 7, 2023
Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag. | J&J’s Janssen has decided to stop a phase 3 trial for a high dose of Opsumit in a subtype of pulmonary hypertension. With the flop, J&J loses a chance to challenge Bayer's Adempas.
MedCity News
SEPTEMBER 4, 2023
By following these foundational data best practices, healthcare organizations will harness the power of their data to provide superior patient care while safeguarding patient privacy and compliance.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
98 
Let's personalize your content